- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07035093
- Original Trial
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)
May 19, 2026 updated by: Eli Lilly and Company
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight.
Participation in the study will last about 80 weeks.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
586
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: LillyTrials@Lilly.com
Study Contact Backup
- Name: Physicians interested in becoming principal investigators please contact
- Email: clinical_inquiry_hub@lilly.com
Study Locations
-
-
-
Buenos Aires, Argentina, C1426ABP
- Recruiting
- Fundación Respirar
-
Principal Investigator:
- Marina Uhrig
-
Contact:
- Phone Number: 5411 7078 1548
-
Buenos Aires, Argentina, C1061AAS
- Recruiting
- CIPREC
-
Contact:
- Phone Number: 5491128690843
-
Principal Investigator:
- Fernando Guerlloy
-
Buenos Aires, Argentina, C1056ABH
- Recruiting
- Investigaciones Medicas IMOBA SRL
-
Contact:
- Phone Number: 05401162076305
-
Principal Investigator:
- Aaron Kruler
-
Buenos Aires, Argentina, C1120AAC
- Recruiting
- Centro Médico Viamonte
-
Principal Investigator:
- Diego Aizenberg
-
Contact:
- Phone Number: 54 1149635650
-
Buenos Aires, Argentina, C1425AGC
- Recruiting
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
-
Contact:
- Phone Number: 541148019001
-
Principal Investigator:
- Maria Coronel
-
Granadero Baigorria, Argentina, 2152
- Recruiting
- Centro de Investigaciones Clínicas Baigorria
-
Contact:
- Phone Number: 543415593898
-
Principal Investigator:
- Juan Escalante
-
Rosario, Argentina, 2000
- Recruiting
- Instituto Médico Catamarca IMEC
-
Contact:
- Phone Number: 3416176661
-
Principal Investigator:
- Natacha Maldonado
-
Rosario, Argentina, 2000
- Recruiting
- Centro Rosarino de Investigaciones Clinicas (CRICs)
-
Contact:
- Phone Number: 03416744474
-
Principal Investigator:
- Juan Loureyro
-
Santa Fe, Argentina, 3000
- Recruiting
- Centro de Diagnóstico y Rehabilitación (CEDIR)
-
Contact:
- Phone Number: 5493424087292
-
Principal Investigator:
- Antonio Saleme
-
-
-
-
-
Brampton, Canada, L6T 0G1
- Recruiting
- Aggarwal and Associates Limited
-
Contact:
- Phone Number: 9054589033
-
Principal Investigator:
- Naresh Aggarwal
-
Hamilton, Canada, L8J 0B6
- Recruiting
- Winterberry Research Inc.
-
Principal Investigator:
- Steven Zizzo
-
Contact:
- Phone Number: 365-366-6267
-
Sarnia, Canada, N7T 4X3
- Recruiting
- Bluewater Clinical Research Group Inc.
-
Principal Investigator:
- John O'Mahony
-
Contact:
- Phone Number: 1 (519) 344-6612
-
Sydney, Canada, B1M 0A1
- Recruiting
- Care Access - Cape Breton
-
Principal Investigator:
- Tony Valente
-
Toronto, Canada, M9V 4B4
- Recruiting
- Dr. Anil K. Gupta Medicine Professional Corporation
-
Contact:
- Phone Number: 6473442020
-
Principal Investigator:
- Anil Gupta
-
-
-
-
-
Bialystok, Poland, 15-756
- Completed
- Podlaskie Centrum Psychogeriatrii
-
-
-
-
Arizona
-
Chandler, Arizona, United States, 85286
- Recruiting
- MD First Research - Chandler
-
Principal Investigator:
- Hemant Pandey
-
Contact:
- Phone Number: 480-508-1038
-
Tucson, Arizona, United States, 85712
- Recruiting
- Tucson Orthopaedic Institute - North Wyatt Drive
-
Principal Investigator:
- Nebojsa Skrepnik
-
Contact:
- Phone Number: 520-404-0276
-
-
California
-
Fountain Valley, California, United States, 92708
- Recruiting
- ARK Clinical Research - Fountain Valley
-
Principal Investigator:
- Justin Yanuck
-
Contact:
- Phone Number: 714-988-2021
-
Fullerton, California, United States, 92835
- Recruiting
- St Joseph Heritage Healthcare
-
Principal Investigator:
- Shirley Pang
-
Contact:
- Phone Number: 714-626-8610
-
Los Angeles, California, United States, 90048
- Recruiting
- Clinical Research Institute
-
Principal Investigator:
- David Kudrow
-
Contact:
- Phone Number: 323-879-9999
-
San Diego, California, United States, 92123
- Recruiting
- Artemis Institute for Clinical Research
-
Contact:
- Phone Number: 858-278-3647
-
Principal Investigator:
- Stacey Layle
-
-
Colorado
-
Boulder, Colorado, United States, 80301
- Recruiting
- Alpine Clinical Research Center
-
Contact:
- Phone Number: 303-443-7229
-
Principal Investigator:
- Paul Brownstone, MD
-
-
Florida
-
Daytona Beach, Florida, United States, 32114
- Recruiting
- K2 Medical Research - Daytona Beach
-
Principal Investigator:
- Joshua Eisenhut
-
Miami, Florida, United States, 33135
- Recruiting
- Flourish Research - Miami, LLC
-
Principal Investigator:
- Mark Kutner
-
Contact:
- Phone Number: 305-631-6704
-
St. Petersburg, Florida, United States, 33704
- Recruiting
- IMA Clinical Research St. Petersburg
-
Contact:
- Phone Number: 727-521-9137
-
Principal Investigator:
- Howard Chipman
-
Tampa, Florida, United States, 33625
- Recruiting
- Care Access - Tampa
-
Principal Investigator:
- Shital Mehta
-
Contact:
- Phone Number: 813-771-5980
-
The Villages, Florida, United States, 32162
- Recruiting
- Charter Research - Lady Lake
-
Principal Investigator:
- Stephen Miller
-
Winter Park, Florida, United States, 32789
- Recruiting
- Conquest Research
-
Principal Investigator:
- Anand Patel
-
Contact:
- Phone Number: 407-916-0060
-
-
Kansas
-
Topeka, Kansas, United States, 66606
- Recruiting
- Cotton O'Neil Clinical Research Center
-
Contact:
- Phone Number: 785-354-9591
-
Principal Investigator:
- Katherine Willingham
-
-
Louisiana
-
Lake Charles, Louisiana, United States, 70601
- Recruiting
- Care Access - Lake Charles (Bayou Pines)
-
Contact:
- Phone Number: 337-602-6642
-
Principal Investigator:
- William Nabours
-
-
Massachusetts
-
Waltham, Massachusetts, United States, 02451
- Recruiting
- MedVadis Research Corporation
-
Contact:
- Phone Number: 617-744-1310
-
Principal Investigator:
- David DiBenedetto
-
-
Michigan
-
Bay City, Michigan, United States, 48706
- Recruiting
- Great Lakes Research Group, Inc.
-
Contact:
- Phone Number: 989-895-9100
-
Principal Investigator:
- Jeffrey Potts
-
-
Missouri
-
Springfield, Missouri, United States, 65807
- Recruiting
- Clinvest Headlands Llc
-
Contact:
- Phone Number: 417-883-7889
-
Principal Investigator:
- Ralph Duda
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
- Recruiting
- Center for Clinical Research
-
Principal Investigator:
- Leonardo Kapural
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Recruiting
- Altoona Center for Clinical Research
-
Principal Investigator:
- Alan Kivitz
-
Contact:
- Phone Number: 814-693-0300
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37909
- Recruiting
- New Phase Research and Development
-
Principal Investigator:
- Natalie Clarke
-
-
Texas
-
Austin, Texas, United States, 78731
- Recruiting
- FutureSearch Trials of Neurology
-
Contact:
- Phone Number: 512-380-9925
-
Principal Investigator:
- Gregory Tempest
-
Dallas, Texas, United States, 75208
- Recruiting
- Mercy Family Clinic
-
Contact:
- Phone Number: 281-944-3610
-
Principal Investigator:
- Ebere Israel Azubuike, MD
-
Houston, Texas, United States, 77079
- Recruiting
- Houston Research Institute
-
Principal Investigator:
- David Huang
-
Contact:
- Phone Number: 281-809-3234
-
-
Virginia
-
Danville, Virginia, United States, 24541
- Recruiting
- Sovah Clinical Research-River District
-
Principal Investigator:
- James Dailey
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Have a history of axial-predominant low back pain
- Have pain that is restricted to the low back or with a referral pattern limited to the proximal legs
- Have a body mass index (BMI) ≥27 kilograms per square meter (kg/m2) at screening
- Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight
Exclusion Criteria:
- Have a non-axial origin low back pain
- Have had botulinum or steroid injections to the spine within 1 year of screening
- Have had trigger point injection to the spine within 6 months of screening
- Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days prior to screening
- Have been taking drugs to promote body weight reduction, including over-the-counter medications, within 90 days prior to screening
- Have a prior or planned surgical treatment for obesity
- Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Participants will receive Placebo SC
|
Administered SC
|
|
Experimental: Retatrutide
Participants will receive Retatrutide subcutaneously (SC)
|
Administered SC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from Baseline in Pain Intensity Per Numeric Rating Scale
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
|
Percent Change from Baseline in Body Weight
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants with Reduction in Pain Intensity Per Numeric Rating Scale
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
|
Number of Participants with Reduction in Body Weight
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
|
Change in Physical Function as Measured by Patient-Reported Outcomes Measurement Information Systems (PROMIS)
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
|
Change in Pain Interference as Measured by PROMIS
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
|
Change in Sleep as Measured by PROMIS
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
|
Change in Patient Reported Health Outcomes as Measured by Medical Outcomes Study 36-item Short Form Health Survey version 2 (SF-36v2)
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
|
Change in Waist Circumference
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
|
Change in Biomarkers of Inflammation as Measured by Blood Test
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
|
Change in Blood Pressure
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
|
Change in Glycemic Control
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
|
Percent Change in Total Cholesterol
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
|
Percent Change in Urine Albumin-to-Creatinine Ratio (UACR)
Time Frame: Baseline, up to 72 weeks
|
Baseline, up to 72 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 29, 2025
Primary Completion (Estimated)
September 1, 2027
Study Completion (Estimated)
September 1, 2027
Study Registration Dates
First Submitted
May 28, 2025
First Submitted That Met QC Criteria
June 16, 2025
First Posted (Actual)
June 24, 2025
Study Record Updates
Last Update Posted (Actual)
May 20, 2026
Last Update Submitted That Met QC Criteria
May 19, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 27278
- 2024-517431-43-00 (Ctis)
- J1I-MC-GZQD (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD Sharing Time Frame
Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later.
Data will be indefinitely available for requesting.
IPD Sharing Access Criteria
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
Beijing Inno Medicine Co., Ltd.The TIMI Study GroupNot yet recruitingCoronary Artery Disease | AtherosclerosisChina